NCT07729553

Brief Summary

This prospective, single-center, cross-sectional observational study aims to evaluate the association between serum 25-hydroxyvitamin D concentrations and lipid profile parameters among adults with obesity and established type 2 diabetes mellitus. A total of 160 participants will be recruited from an outpatient diabetes clinic in Cairo, Egypt. Each participant will undergo a single clinical, anthropometric, and laboratory assessment. No intervention or treatment will be assigned by the investigators.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Jul 2026

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
Jul 2026Feb 2027

First Submitted

Initial submission to the registry

July 22, 2026

Completed
3 days until next milestone

Study Start

First participant enrolled

July 25, 2026

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 27, 2026

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2027

Last Updated

July 27, 2026

Status Verified

July 1, 2026

Enrollment Period

5 months

First QC Date

July 22, 2026

Last Update Submit

July 22, 2026

Conditions

Keywords

Type 2 Diabetes MellitusObesity; Vitamin D Deficiency; Dyslipidemia; Lipid MetabolismCardiometabolic Risk

Outcome Measures

Primary Outcomes (1)

  • Lipid Profile According to Serum 25-Hydroxyvitamin D Status

    Measurement of serum lipid parameters including: Total cholesterol (mg/dL) Triglycerides (mg/dL) High-density lipoprotein cholesterol (HDL-C, mg/dL) Low-density lipoprotein cholesterol (LDL-C, mg/dL)

    At the baseline study visit (single assessment)

Secondary Outcomes (4)

  • Fasting Blood Glucose

    At the baseline study visit (single assessment)

  • Postprandial Blood Glucose

    At the baseline study visit (single assessment)

  • Glycated Hemoglobin (HbA1c)

    At the baseline study visit (single assessment)

  • Serum Insulin

    At the baseline study visit (single assessment)

Study Arms (2)

Lower Vitamin D Status Group

Participants with obesity and established type 2 diabetes mellitus who have lower serum 25-hydroxyvitamin D \[25(OH)D\] concentrations according to the predefined study criteria. Vitamin D deficiency is defined as serum 25(OH)D concentration below 20 ng/mL. Participants in this group will undergo clinical and laboratory assessments, including lipid profile and glycemic measurements, to evaluate metabolic characteristics associated with lower vitamin D status.

Higher Vitamin D Status Group

Participants with obesity and established type 2 diabetes mellitus who have higher serum 25-hydroxyvitamin D \[25(OH)D\] concentrations according to the predefined study criteria. Participants in this group will undergo the same clinical and laboratory assessments, including lipid profile and glycemic measurements, for comparison with the lower vitamin D status group.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults with obesity and established type 2 diabetes mellitus attending an outpatient diabetes clinic.

You may qualify if:

  • Adults aged 18 years or older.
  • Established diagnosis of type 2 diabetes mellitus (T2DM) according to standard diagnostic criteria.
  • Obesity based on body mass index (BMI) criteria.
  • Availability of serum 25-hydroxyvitamin D \[25(OH)D\] measurement.
  • Availability of lipid profile and glycemic laboratory parameters.
  • Ability and willingness to provide written informed consent.

You may not qualify if:

  • Type 1 diabetes mellitus.
  • Pregnancy.
  • Known chronic kidney disease.
  • Chronic liver disease.
  • Active malignancy.
  • Acute infection or inflammatory disease.
  • Conditions affecting gastrointestinal absorption.
  • Use of medications or supplements that substantially alter vitamin D metabolism (when applicable).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes Mellitus, Type 2ObesityDyslipidemiasVitamin D Deficiency

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsLipid Metabolism DisordersAvitaminosisDeficiency DiseasesMalnutrition

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer

Study Record Dates

First Submitted

July 22, 2026

First Posted

July 27, 2026

Study Start

July 25, 2026

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

February 28, 2027

Last Updated

July 27, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared publicly. The study data contain potentially identifiable health information, and participant consent and institutional ethical approval did not include unrestricted public release of individual-level data. Requests for data access may be considered by the corresponding author upon reasonable request and subject to institutional and ethical approval.